2bind GmbH Appoints Dr. Thomas Schubert as CEO to Lead Strategic Shift Towards Drug Discovery Research Services
June 2017 – 2bind GmbH today announces the appointment of Dr. Thomas Schubert as its new Chief Executive Officer. Dr. Schubert, with a PhD in biochemistry from the University of Regensburg, brings a wealth of experience in applying cutting-edge biophysical techniques to solve complex scientific challenges. Dr. Schubert’s appointment marks a strategic shift for 2bind, as the company expands its focus to provide high-quality research services to clients and customers in the biotech and pharmaceutical industries. His early adoption of innovative biophysical techniques like MicroScale Thermophoresis (MST) demonstrates his passion for pushing the boundaries of scientific discovery.
“I am honored to join 2bind as CEO. The company has a strong foundation in biophysics, and I am committed to leveraging this expertise to build a recognized contract research organization. I look forward to working with the talented team at 2bind to empower our clients with the insights and solutions they need to accelerate drug discovery and development.”
Dr. Thomas Schubert
